Section of General Internal Medicine, Boston University Chobanian and Avedisian School of Medicine and Boston Medical Center, 801 Massachusetts Avenue, Second Floor, Boston, MA, 02118, USA.
Grayken Center for Addiction, Boston Medical Center, Boston, MA, USA.
Addict Sci Clin Pract. 2024 Nov 4;19(1):77. doi: 10.1186/s13722-024-00502-5.
Addiction medicine providers have a key role in HIV prevention amidst rising HIV incidence in persons who inject drugs (PWID). Pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) are vastly underutilized in this population. Inpatient hospitalization represents a potential touchpoint for initiation of HIV prophylaxis, though little research explores the role of addiction providers. Here we describe rates of PrEP/PEP delivery to hospitalized PWID seen by an Addiction Consult Service (ACS) at an urban, essential hospital.
We performed a cross-sectional study of hospitalized patients who were seen by the ACS from January 1, 2020 to December 31, 2022 and had plausible injection drug use. We calculated the proportion of patients who received a new prescription for PrEP/PEP at discharge. We used descriptive statistics to characterize demographics, substance use, reason for admission, and indications for PrEP/PEP. Secondarily, we calculated the monthly proportion of all patients discharged from the hospital with PrEP/PEP who were seen by the ACS compared to those not seen by the ACS.
The average monthly proportion of ACS consults with plausible injection drug use who received PrEP/PEP was 6.4%. This increased from 4.2% in 2020 to 7.5% in 2022. Those seen by the ACS who received PrEP/PEP had high rates of opioid use disorder (97.5%), stimulant use disorder (77.8%), and homelessness (58.1%); over half were admitted for an injection-related infection. The indications for PrEP/PEP were injection drug use only (70.6%), followed by combined injection and sexual risk (20.2%); 71.9% of prescriptions were for PrEP and 28.1% for PEP. Overall, the ACS was involved in 83.9% of hospital-wide discharges with PrEP/PEP prescriptions (n = 242).
PWID who were seen by the ACS received PrEP/PEP prescriptions at rates exceeding national averages. The ACS was also involved with the care of the majority of admitted patients who received PrEP/PEP at discharge. While PrEP/PEP use for PWID remains low, the inpatient ACS represents a key resource to improve uptake by leveraging the reachable moment of an inpatient hospitalization.
在注射吸毒者(PWID)中 HIV 发病率上升的情况下,成瘾医学提供者在 HIV 预防方面发挥着关键作用。暴露前预防(PrEP)和暴露后预防(PEP)在该人群中未得到充分利用。住院治疗代表了开始 HIV 预防的潜在接触点,尽管很少有研究探讨成瘾提供者的作用。在这里,我们描述了在城市基本医院的成瘾咨询服务(ACS)就诊的住院 PWID 中 PrEP/PEP 的提供率。
我们对 2020 年 1 月 1 日至 2022 年 12 月 31 日期间由 ACS 接诊且可能存在注射药物使用情况的住院患者进行了一项横断面研究。我们计算了出院时新开具 PrEP/PEP 处方的患者比例。我们使用描述性统计来描述人口统计学特征、物质使用、入院原因和 PrEP/PEP 的适应证。其次,我们计算了每月从医院出院并接受 ACS 治疗的 PrEP/PEP 患者比例,与未接受 ACS 治疗的患者进行比较。
平均每月 ACS 咨询中有注射药物使用的患者接受 PrEP/PEP 的比例为 6.4%。这一比例从 2020 年的 4.2%增加到 2022 年的 7.5%。接受 PrEP/PEP 的 ACS 就诊者中,阿片类药物使用障碍(97.5%)、兴奋剂使用障碍(77.8%)和无家可归(58.1%)的发生率较高;超过一半的人因与注射相关的感染而入院。PrEP/PEP 的适应证仅为注射药物使用(70.6%),其次是注射和性行为风险的综合风险(20.2%);71.9%的处方为 PrEP,28.1%为 PEP。总体而言,ACS 参与了 83.9%的有 PrEP/PEP 处方的全院出院患者的治疗(n=242)。
接受 ACS 治疗的 PWID 接受 PrEP/PEP 处方的比例超过全国平均水平。ACS 还参与了大多数接受 PrEP/PEP 出院的住院患者的治疗。虽然 PWID 中 PrEP/PEP 的使用仍然很低,但住院 ACS 代表了通过利用住院治疗的可及时刻来提高使用率的关键资源。